Background: Positron emission tomography combined with computed tomography (PET-CT) is important in the assessment and workup of lung cancer staging. However, inconsistencies between clinical image results obtained and pathologic findings of surgical specimens are still very common, particularly in patients with clinical early stage lung cancer. We sought to clarify the role of PET-CT in predicting mediastinal lymph node status preoperatively in clinical early stage lung cancer patients. Methods: The cases were collected retrospectively from January 2008 to February 2009. All patients were good surgical candidates, and clinically early-stage during the pre-op evaluation, which included CT, PET scan, and cardiopulmonary tests. All patients underwent surgery, with complete pathological evaluation of mediastinal lymph node (LNs). The pathological status and PET Standardized uptake value (SUV) max of mediastinal LNs were collected to calculate the ROC curve, and to determine the best cut-off value of PET SUV max . Other cofactors, including sex, tumor size, tumor SUV max , histology type, and lobar distribution, were analyzed utilizing correlation study, Chi-square test, and ttest for significance. Results: A total of 83 patients were enrolled into the study. The majority of the cases were in pathological early stage (Stage I: 67.5%, Stage II: 12%). The cut-off point of mediastinal LN SUV max was 1.6 calculated by receiver operating characteristic (ROC) curve (sensitivity: 40%, specificity: 88.7%, negative predictive rate: 95.1%). The hilar LN SUV max was found to have a poor correlation to the final pathologic status of hilar nodes with insignificant p value (0.487). Tumor SUV max and increased hilar LN uptake (SUV max > 2.0) were found to be significantly correlated with the pathologic status of mediastinal LNs. The false positive rates by PET-CT scan in N1 and N2 nodes were 70% and 78%, respectively, primarily due to inflammatory process (as anthracosis the leading cause). Conclusion: Integrated PET-CT is a useful tool for predicting the negativity of mediastinal LN status pre-operatively in clinically early stage (Stages I and II) lung cancer but may be relatively inaccurate in predicting hilar LN status and largely confounded by false positives caused by inflammatory process.
Introduction
Lung cancer is the leading cause of cancer mortality worldwide for both men and women, causing approximately 1.2 million deaths per year. 1 In the United States in 2010, there will have about 222,450 estimated new cases of lung cancer in both men and women and approximately 157,300 lung cancerrelated deaths. 2 The treatment for lung cancer depends on the histological type of tumor (small cell versus non-small cell) and its extent (stage). For patients with non-small-cell lung cancer (NSCLC), accurate staging is crucial to assist the practitioner and patient to determine a proper treatment plan, which may include surgery and/or chemoradiotherapy.
From the technology of positron emission tomography (PET) came into use clinically, several studies have demonstrated its effectiveness in both improving preoperative assessments, and decreasing numbers of futile thoracotomies which are conducted. 3 The former attempt to integrate both positron emission tomography and computed tomography (CT), further improving its diagnostic power and was proven to significantly increasing the accuracy of staging in NSCLC; it also enhanced the ability of practitioners to predict stage I and II disease and T and N staging (compared with PET alone). 4 In recent studies, integrated PET-CT has been proven to be highly specific with a high negative predictive rate (85 AE 11%). However, the low sensitivity and low positive predictive rate of PET-CT has also been recognized. 5 The sensitivity of PET scanning in staging the mediastinum was reported to vary from 0.5 to 1.0 in previous studies. 6 Those studies suggest that patients with negative PET-CT results may be reasonably proceeding to surgery without invasive mediastinal staging, due to the high negative predictive rate of PET-CT. On the other hand, the decision whether or not to perform a mediastinoscopy for those who have increase uptake over PET-CT, and the best cutoff value of Standardized uptake value (SUV) max still remains in debate.
With the popularization of advanced imaging modalities, an increasing number of potentially malignant lung lesions are being discovered. Among these technologies, PET-CT imaging can play a role in predicting mediastinal lymph node status pre-operatively, for those who might be patients of early stage lung cancer without significant mediastinal lymphadenopathies after CT scan. There have been different cut-off values of SUV max of mediastinal lymph node recommended by various studies, ranging from 2.5e5.3. 5 We also noted that, while managing cases with clinically early stage lung cancer without significant mediastinal lymphadenopathies over CT scan, false positives of mediastinal lymph node often confounded our interpretation of the preoperative PET-CT results. Therefore, the aim of this study is to determine the best cut-off value of SUV max over PET-CT, utilizing the data pool in our medical center, and to ascertain cofactors that may be correlated to the final pathologic status of mediastinal lymph nodes.
Methods
From January 2008 to February 2009, 83 patients with pathologically proven NSCLC were collected retrospectively into the study. All patients went through preoperative work-up, including physical examinations, laboratory tests, CT, PET-CT scan, and cardiopulmonary testing, and, thereafter, underwent definitive surgery with radical lymph node dissection. Surgery and all preoperatives examinations occurred only after obtaining inform consent from each patient. All patients were determined to have insignificant mediastinal lymph nodes (with shortest diameter <1 cm on contrast-enhanced CT scan) and were clinically staged as Stage I or II. No distant metastatic lesion was found by pre-operative PET-CT in all 83 patients. Mediastinoscopic biopsy was routinely performed in patients with significant mediastinal lymphadenopathies over the preoperative CT scan in our center and was therefore not performed on the 83 patients enrolled. Complete pathologic lymph node (LN) staging were obtained in all patients.
PET-CT imaging
All patients were asked to fast at least 6 hours before the fluorodeoxyglucose-PET examination. Blood sugar levels were checked and confirmed to be less than 150 mg/dl before injection of the fluorodeoxyglucose. The PET-CT imaging was obtained from head to upper portion of the thigh on an integrated PET-CT scanner (Discovery VCT; GE Healthcare, Waukesha, Wisconsin, USA) 60 minutes after intravenous injection of 10 mCi (370 MBq) of fluorodeoxyglucose. Lowdose CT for attenuation correction was performed first with a 64-slice multidetector computed tomography, which was followed by the PET scan. The raw data of PET imaging was reconstructed into a 128 Â 128 matrix with the use of an iterative reconstruction algorithm (iteration 2, subset 28).
SUV measurement
For quantitative analysis of fluorodeoxyglucose uptake, SUV was assessed on the Xeleris Workstation (GE Healthcare, Waukesha, Wisconsin, USA). The maximal SUV of the primary lung tumors, hilar and mediastinal lymph nodes was measured by drawing a 1.0-cm diameter region of interest (ROI) on the slice with the highest fluorodeoxyglucose uptake. The LNs with SUV max greater than 2.0 are considered measurable. For nonmeasurable nodes, we adopted the bloodpool SUV to represent the uptake of these nodes for the ROC analysis. In order to calculate the blood-pool SUV, we randomly selected 20 patients, drew a 1.0-cm ROI in the center of the superior vena cava on three consecutive slices in each patient, and recorded the mean SUV in the region of interest. The mean of the 60 selected ROIs was calculated to represent the blood-pool SUV, which was calculated as 1.27. Any nodal uptake over the value of 1.27 will be recorded and finally compared with the pathology report for plotting the receiver operating characteristic (ROC) curve.
Surgical resection
All patients underwent resection through video-assisted thoracoscopy or a posterolateral thoracotomy. A systematic approach of LN dissection was carried out in all patients: in left side lung cancers, LN station 4, 5, 6, and 7 are routinely dissected; in right side lung cancers, lymph node station 2, 3, 4, and 7 are routinely dissected. Finally, a total number of 281 mediastinal nodal stations were dissected from 83 patients (average 3.4 nodal station in each patient). All pathologic specimens were examined by experienced pulmonary pathologists using standard technique and immunohistochemical stain. The final pathologic LN staging was compared station by station with the preoperative PET-CT scan.
Statistical analysis
The software package SPSS v17.0 (SPSS Inc., Chicago, IL, USA) was used to perform the statistical analysis. The pathological status and SUV max of mediastinal lymph nodes were collected for calculating ROC curve and determining the cutoff value of SUV max . Other co-factors including gender, tumor size, tumor SUV max , histology type, lobar distribution were analyzed with correlation study, Chi-square test, and t-test for significance. The p values were considered as statistically significant if <0.05.
Results
Our retrospective study included 45 male patients and 38 female patients with age ranges of 36 w 89 and mean (AESD) of 66 (AE12). All patients received definitive surgery intended for cure. Among them, 80 received lobectomy (96.4%), two received pneumonectomy due to encasement of posterior ascending artery and common basal artery, respectively, and one received right upper lobe lobectomy and right middle lobe wedge resection due to lung-to-lung metastasis found intraoperatively. The final pathologic tumor-node-metastasis (TNM) staging of our patients was mostly in early stage (Stage I: 67.5%; Stage II: 12%; Stage III: 19.3%; Stage IV: 1.2%), and adenocarcinoma was the predominant histological type among all patients. The false negative rate predicted by preoperative CT scan was 18.1% (15 patients was finally found to have pathological N2 disease among 83 cases). Other variables including lobar distribution, tumor size, pathologic grading, and tumor SUV max were listed in Table 1 .
When correlating the relationship between the SUV max of mediastinal (N2) and hilar (N1) nodes and their pathological status, the value of SUV max was found to be significantly higher in the pathologically positive mediastinal nodes (2.18 AE 1.51 vs. 1.46 AE 0.61, p ¼ 0.049). However, among hilar nodes, the differences were not significant (2.20 AE 1.21 vs. 1.84 AE 1.10, p ¼ 0.487), even when excluding the cases with bilateral hilar uptake (2.04 AE 1.19 vs. 1.65 AE 1.08, p ¼ 0.317). The cut-off values of SUV max of N1 and N2 node calculated by ROC curve were 2.0 and 1.6 (see Fig. 1 ), respectively. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) calculated by the cut-off value mentioned above were listed in Table 2 .
All factors, including tumor SUV max , tumor size on CT image, pathological tumor size, sex, histology, lobar distribution, and pathologic grading of tumor, were correlated with pathologic hilar and mediastinal LN status. Among all factors, tumor SUV max , sex, and increased hilar nodal uptake over PET-CT (SUV max > 2.0) were significantly correlated with mediastinal LN pathologic status (Table 3) ; only tumor SUV max was significantly correlated with hilar lymph node pathological status (Table 4) .
When comparing with cases without increased uptake of hilar LN on PET-CT, those with increased uptake of hilar LN (SUV max > 2.0) were found to possess higher risk of having pathologically positive N2 nodes [relative risk (RR): 2.5; odds . By excluding the cases with bilateral hilar uptake and considering only the cases with ipsilateral hilar LN uptake, we acquired even higher RR and OR (3.8 and 4.3, respectively). Fig. 2 is a fine example for the findings mentioned above. The false positives of N1 and N2 nodes were calculated and classified by the pathology report. The common causes of false positive nodes were anthracosis, reactive hyperplasia, hyalinized granuloma, and necrotizing granulomatous inflammation. The false positive rates by PET-CT scan in N1 and N2 nodes were 70% and 79%, respectively. If cases of bilateral hilar uptake were excluded, the false positive rate of N1 nodes will decrease to 53.8%. In both N1 and N2 nodes, the most common cause of false positives was anthracosis, which was inflammatory in nature.
Discussion
In our study, we use the ROC curve for determining the cutoff value of SUV max to most effectively predict the mediastinal LN status. The SUV max was calculated to be 1.6, and was comparatively lower than those values of 2.5 w 5.3 proposed by other studies. 4, 5, 7, 8 Nevertheless, when using this cutoff SUV max of 1.6 for calculating the sensitivity and specificity (sensitivity: 40%, specificity: 88.7%), we still have results compatible with other studies, in which the specificity were high and ranged from 85%e94%. 4, 5, 7, 8 On the other hand, the sensitivity was variable and ranged from 40%e91%, which may be caused by the commonly observed inflammatory change over mediastinal lymph nodes. The differences in the cutoff SUV max thresholds between our studies and others are possibly related to the ratio of advanced stage lung cancer examined in the different studies. Fig. 1 . The ROC curve for determining the cutoff value (SUV max ) of mediastinal LN; at cutoff value of 1.6, the sensitivity and specificity are 40% and 88.9%, respectively. LN, lymph node; ROC curve, receiver operating characteristic curve; SUV ¼ standardized uptake value. In our study, early stage lung cancer (Stages I and II) accounts for 80% of cases, which may explain the lower cutoff value of N2 nodes comparing to other studies. The SUV max of hilar LN was poorly correlated to the final pathologic status, even when excluding cases of bilateral hilar uptake. With this result, PET-CT seems to be more useful in predicting mediastinal rather then hilar LN status. The accuracy (number of true positive and true negative divided by total case number) in predicting N1 and N2 nodal status by PET-CT in our study is 65% and 85%, respectively. According to the study of Cerfolio and colleagues, 4 the accuracy of PET-CT in evaluating mediastinal LNs is observed to be higher then the accuracy in evaluating hilar LNs, which was compatible with our observations. The overall false positive rate of predicting hilar nodal status by PET-CT was 70%, and it would decrease to 53.8% if cases of bilateral hilar uptake were excluded. Most of the false positive cases are due to anthracosis, followed by reactive hyperplasia and hyalinized granuloma. These results can also be observed in other studies, in which LN inflammation is usually the leading cause of false positive results of PET-CT. 9, 10 The inflammation can be secondary to infection, such as tuberculosis, or may be non-infectious or related to environmental factors, which may be the contributing factor of the inaccuracy of PET-CT in evaluating hilar LNs. 5, 11 In terms of predicting N2 nodal status of clinically early stage lung cancer by PET-CT, a high false positive rate of 79% was found. The most common cause was also noted to be anthracosis and hyalinized granuloma. Previous studies have observed that the type of false positive mediastinal LNs over PET-CT was related to regional factors. 7 For instance, silicosis has been found to be a cause of false positives in Germany, and histoplasmosis is more prevalent as a cause of false positives in the southeastern United States. The endemic granulomatous infection seems to play an important role in increasing false positive rates of PET-CT. In our experiences and observations, anthracosis and granulomatous inflammation are both important causes of false positive in both N1 and N2 nodal group.
Among all factors which may be correlated to or have impact on the final pathologic status of mediastinal LNs, only the value of tumor SUV max , positive hilar uptake (SUV max > 2.0), and sex difference are statistically significant. In our study, the positive rate of mediastinal LN metastasis is significantly higher in female group. Meanwhile, we also observed a higher ratio of adenocarcinoma in the female group (92.3% in female vs. 68.8% in male, p ¼ 0.007), which is compatible with the known phenomenon that glandular differentiation is more popular in women.
12e14 The histological difference between two sexes may also explain the increased positive rate of mediastinal LN in female patients according to the study of Sagawa and colleagues, 15 which noted that lymphatic invasion and LN metastases are common early in the course of adenocarcinoma. Therefore, we considered that the influence of sex on the pathologic N2 nodal status may be due to the patient characteristics, and, thus, does not represent a true phenomenon.
There are still limitations in our study, which primarily arise from its retrospective nature. PET-CT in itself is an imaging modality with great variability in its sensitivity and a relatively high false positive rate. It is also easily confounded due to inflammatory process and endemic granulomatous infection, especially in cases with early stage lung cancer. The high negative predictive rate (95.1%) makes PET-CT a useful tool in sparing selected patients from unnecessary invasive mediastinoscopic biopsy. The results garnered from our study should be further tested with prospective or randomized trial for clinical application and evaluation of usefulness.
In conclusion, Integrated PET-CT is a useful tool for predicting the negativity of mediastinal LN status preoperatively in the clinically early stages of lung cancer (Stages I and II), but it may be relatively inaccurate in predicting hilar LN status and be confounded by false positives caused by inflammatory process. Patients with mediastinal LN uptake <1.6 may go directly to definitive surgery without a mediastinoscopy. On the contrary, for patients with mediastinal LN SUV max > 1.6 combined with ipsilateral hilar lymph node SUV max > 2.0, it is strongly recommended that they receive mediastinoscopic LN biopsy for an accurate staging.
